The contribution of type-I IFN-mediated neuroinflammation to Parkinson's disease progression
Parkinson's disease (PD) is a chronic neurodegenerative disease characterized by motor dysfunction. Pathological hallmarks of the disease include selective dopaminergic neuronal death, intraneuronal deposits known as Lewy bodies and extensive neuroinflammation within the central nervous system...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Brain, Behavior, & Immunity - Health |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666354625000754 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849336202891624448 |
|---|---|
| author | Shuyan Chen Peter J. Crack Juliet M. Taylor |
| author_facet | Shuyan Chen Peter J. Crack Juliet M. Taylor |
| author_sort | Shuyan Chen |
| collection | DOAJ |
| description | Parkinson's disease (PD) is a chronic neurodegenerative disease characterized by motor dysfunction. Pathological hallmarks of the disease include selective dopaminergic neuronal death, intraneuronal deposits known as Lewy bodies and extensive neuroinflammation within the central nervous system (CNS). Microglia are the key cellular players in mediating this neuroinflammatory response, propagating this neuropathology to exacerbate the neuronal cell death. Growing evidence suggests a role for the type-I interferons (IFN) in driving the neuroinflammatory response in PD, with increased type-I IFN signatures reported in both PD patients and in animal models of the disease. This review will discuss 1) the key players that modulate the neuroinflammatory response in PD and their implications in the CNS 2) the contribution of the type-I IFNs in driving the neuroinflammatory response in PD, and 3) evidence for therapeutically targeting type-I IFN signalling to slow disease progression. A greater understanding of the underlying mechanisms that lead to the elevated neuroinflammatory response in PD could lead to new advances in therapeutic targets that effectively slow the disease progression. |
| format | Article |
| id | doaj-art-82f18445ccec4ee594888b80c33e3584 |
| institution | Kabale University |
| issn | 2666-3546 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Brain, Behavior, & Immunity - Health |
| spelling | doaj-art-82f18445ccec4ee594888b80c33e35842025-08-20T03:45:03ZengElsevierBrain, Behavior, & Immunity - Health2666-35462025-07-014610101710.1016/j.bbih.2025.101017The contribution of type-I IFN-mediated neuroinflammation to Parkinson's disease progressionShuyan Chen0Peter J. Crack1Juliet M. Taylor2Neuropharmacology Laboratory, Department of Biochemistry and Pharmacology, University of Melbourne, Parkville, AustraliaCorresponding author. Neuropharmacology Laboratory, Department of Biochemistry and Pharmacology, Level 5, Bio21 Institute, University of Melbourne, Parkville, 3010, Australia.; Neuropharmacology Laboratory, Department of Biochemistry and Pharmacology, University of Melbourne, Parkville, AustraliaNeuropharmacology Laboratory, Department of Biochemistry and Pharmacology, University of Melbourne, Parkville, AustraliaParkinson's disease (PD) is a chronic neurodegenerative disease characterized by motor dysfunction. Pathological hallmarks of the disease include selective dopaminergic neuronal death, intraneuronal deposits known as Lewy bodies and extensive neuroinflammation within the central nervous system (CNS). Microglia are the key cellular players in mediating this neuroinflammatory response, propagating this neuropathology to exacerbate the neuronal cell death. Growing evidence suggests a role for the type-I interferons (IFN) in driving the neuroinflammatory response in PD, with increased type-I IFN signatures reported in both PD patients and in animal models of the disease. This review will discuss 1) the key players that modulate the neuroinflammatory response in PD and their implications in the CNS 2) the contribution of the type-I IFNs in driving the neuroinflammatory response in PD, and 3) evidence for therapeutically targeting type-I IFN signalling to slow disease progression. A greater understanding of the underlying mechanisms that lead to the elevated neuroinflammatory response in PD could lead to new advances in therapeutic targets that effectively slow the disease progression.http://www.sciencedirect.com/science/article/pii/S2666354625000754NeuroinflammationAgingType-I interferonsParkinson's diseaseMicroglia |
| spellingShingle | Shuyan Chen Peter J. Crack Juliet M. Taylor The contribution of type-I IFN-mediated neuroinflammation to Parkinson's disease progression Brain, Behavior, & Immunity - Health Neuroinflammation Aging Type-I interferons Parkinson's disease Microglia |
| title | The contribution of type-I IFN-mediated neuroinflammation to Parkinson's disease progression |
| title_full | The contribution of type-I IFN-mediated neuroinflammation to Parkinson's disease progression |
| title_fullStr | The contribution of type-I IFN-mediated neuroinflammation to Parkinson's disease progression |
| title_full_unstemmed | The contribution of type-I IFN-mediated neuroinflammation to Parkinson's disease progression |
| title_short | The contribution of type-I IFN-mediated neuroinflammation to Parkinson's disease progression |
| title_sort | contribution of type i ifn mediated neuroinflammation to parkinson s disease progression |
| topic | Neuroinflammation Aging Type-I interferons Parkinson's disease Microglia |
| url | http://www.sciencedirect.com/science/article/pii/S2666354625000754 |
| work_keys_str_mv | AT shuyanchen thecontributionoftypeiifnmediatedneuroinflammationtoparkinsonsdiseaseprogression AT peterjcrack thecontributionoftypeiifnmediatedneuroinflammationtoparkinsonsdiseaseprogression AT julietmtaylor thecontributionoftypeiifnmediatedneuroinflammationtoparkinsonsdiseaseprogression AT shuyanchen contributionoftypeiifnmediatedneuroinflammationtoparkinsonsdiseaseprogression AT peterjcrack contributionoftypeiifnmediatedneuroinflammationtoparkinsonsdiseaseprogression AT julietmtaylor contributionoftypeiifnmediatedneuroinflammationtoparkinsonsdiseaseprogression |